Focus: Athena Bioscience is a specialty pharmaceutical company headquartered in Watkinsville, GA, focused on neurology and pain management with a portfolio of marketed specialty drugs.
Profile data last refreshed 3h ago · AI intelligence enriched 1w ago
Growing — net +8 jobs in 30d
10 jobs added vs 2 removed. Steady team buildout.
Athena offers stable legacy product revenue but faces execution risk from recent layoffs, no pipeline innovation, and minimal hiring in core pharmaceutical roles—suitable only for specialists seeking operational/administrative stability over growth opportunity.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Alpha-2 adrenergic agonist in peak revenue phase with patent protection until 2031, representing a mature franchise asset.
Help build intelligence for Athena Bioscience
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from Athena Bioscience's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Opioid analgesic with extended patent life to 2040, providing longest LOE runway in the company's portfolio.
Peroxisome proliferator-activated receptor agonist approaching patent cliff in 2027, represents near-term revenue decline risk.
2 discontinued, 0 duplicate formulations not shown
Based on last 4 crawl cycles
Source: USCIS H-1B Employer Data Hub
Source: state DOL filings, aggregated via Big Local News
Recent large-scale layoff coupled with zero pipeline and minimal hiring suggests elevated job security risk and potential for further organizational changes.
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/mo